(RMD) ResMed - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7611521078
RMD: Devices, Software, Therapies, Diagnostics, Solutions, Equipment
ResMed Inc., a leader in the sleep and respiratory care industry, is at the forefront of the health tech revolution. As a prominent figure in this space, ResMed is capitalizing on the growing awareness of sleep disorders and the increasing demand for remote patient monitoring solutions, especially in the post-pandemic era.
The companys product portfolio is a blend of hardware and software, designed to cater to both clinical and operational needs. On the hardware side, ResMed offers devices like ApneaLink Air and NightOwl, which provide comprehensive diagnostic data essential for accurate patient assessments. These tools are complemented by software solutions such as AirView and myAir, which enhance patient engagement and streamline care management, reflecting ResMeds commitment to integrating technology into healthcare delivery.
ResMeds out-of-hospital software solutions, including Brightree and MatrixCare, are pivotal for managing operations in home healthcare and related services. These platforms not only improve efficiency but also position ResMed as a comprehensive solution provider in the healthcare sector.
The companys distribution strategy, combining direct sales and a robust network of distributors, ensures their products reach sleep clinics, home healthcare providers, and hospitals effectively. This strategic approach underscores ResMeds ability to meet market demands comprehensively.
Financially, ResMed boasts a market cap of over $34 billion, with valuation multiples indicating a company poised for growth. Their focus on expanding software capabilities through strategic acquisitions, coupled with advancements in data analytics and AI, underscores their commitment to innovation and operational efficiency.
In summary, ResMeds diversified product range, strong distribution network, and strategic acquisitions make it a compelling investment in the growing healthcare technology industry. Their comprehensive solutions position them as a leader, aligning with the trends driving the future of healthcare.
Additional Sources for RMD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RMD Stock Overview
Market Cap in USD | 30,133m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1995-06-02 |
RMD Stock Ratings
Growth Rating | 25.1 |
Fundamental | 91.9 |
Dividend Rating | 55.6 |
Rel. Strength | 24.3 |
Analysts | 3.72/5 |
Fair Price Momentum | 201.69 USD |
Fair Price DCF | 207.77 USD |
RMD Dividends
Dividend Yield 12m | 0.94% |
Yield on Cost 5y | 1.31% |
Annual Growth 5y | 5.30% |
Payout Consistency | 100.0% |
RMD Growth Ratios
Growth Correlation 3m | -94.1% |
Growth Correlation 12m | 44.5% |
Growth Correlation 5y | 18.9% |
CAGR 5y | 6.21% |
CAGR/Max DD 5y | 0.11 |
Sharpe Ratio 12m | 0.40 |
Alpha | 14.90 |
Beta | 0.737 |
Volatility | 31.00% |
Current Volume | 1109.6k |
Average Volume 20d | 1098.1k |
As of April 18, 2025, the stock is trading at USD 212.91 with a total of 1,109,562 shares traded.
Over the past week, the price has changed by +1.12%, over one month by -5.26%, over three months by -11.01% and over the past year by +23.59%.
Yes, based on ValueRay Fundamental Analyses, ResMed (NYSE:RMD) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 91.88 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RMD as of April 2025 is 201.69. This means that RMD is currently overvalued and has a potential downside of -5.27%.
ResMed has received a consensus analysts rating of 3.72. Therefor, it is recommend to hold RMD.
- Strong Buy: 6
- Buy: 3
- Hold: 8
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, RMD ResMed will be worth about 221.6 in April 2026. The stock is currently trading at 212.91. This means that the stock has a potential upside of +4.06%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 269.4 | 26.5% |
Analysts Target Price | 256 | 20.2% |
ValueRay Target Price | 221.6 | 4.1% |